An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies

IntroductionCytokine release syndrome (CRS) is a potentially severe systemic inflammatory condition triggered by various immunomodulatory therapies, making understanding its pathogenesis critical for improving patient outcomes.Results/MethodsBy combining immunotoxicology and systems biology approach...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alexander Mazein, Oxana Lopata, Kristin Reiche, Katherina Sewald, Miriam Alb, Christina Sakellariou, Patricia Gogesch, Hannah Morgan, Vanessa Neuhaus, Nhu-Nguyen Pham, Charline Sommer, Ethan Perkins, Birgit Fogal, Muhammad Shoaib, Reinhard Schneider, Venkata Satagopam, Marek Ostaszewski
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	systems biology systems toxicology immunomodulatory therapies adverse outcome pathway (AOP) cytokine release syndrome (CRS) CAR T cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601670/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies

Similar Items